Striverdi respimat generic when will it be launched?

What is Striverdi Respimat?
Striverdi Respimat is a brand inhaler that delivers formoterol fumarate, a long‑acting β‑agonist used for asthma and COPD. The Respimat device is a soft‑mist inhaler that provides a fine aerosol mist, which patients inhale over several seconds. The drug and the device together form the product that patients purchase under the Striverdi brand.

How the FDA approves generics for inhalers
A generic inhaler must meet the FDA’s “absolutely equivalent” standard. That means the generic’s drug content, device performance, safety, and labeling must match the brand in every relevant way. For Respimat‑style inhalers, the FDA evaluates the device’s spray pattern, dose delivery, and patient usability through bench and clinical studies before granting approval [1].

Why there’s no launch date yet
No public announcement from the manufacturer or the FDA lists a launch date for a Striverdi generic. Generic sponsors typically file a “Abbreviated New Drug Application” (ANDA) after the brand’s patent and exclusivity periods end. The review period can last 12–18 months, and the sponsor must still negotiate pricing and market access before the product hits shelves. Until the FDA grants approval and the sponsor completes these steps, a launch date remains undefined.

When to expect updates
The FDA publishes a “Generic Drugs” list that is updated whenever a new generic receives approval. Checking this list or the FDA’s “Drug Approvals & Databases” portal can reveal whether a formoterol Respimat generic has cleared review. Additionally, the FDA’s “Daily MedWatch” or the “Drug Approval News” RSS feed often includes announcements for newly approved inhalers.

Who’s developing the generic?
Several generic manufacturers have expressed interest in formoterol inhalers, but no one has announced a specific plan to launch a Striverdi‑like Respimat product. Companies that already produce formoterol soft‑mist inhalers will likely be the first to file ANDAs, but the timeline depends on each company’s regulatory strategy and resource allocation.

What could delay the launch
Even after FDA approval, a generic may face delays from:
- Supply chain issues – sourcing the precise inhaler components can be challenging.
- Pricing negotiations – generics often face pushback from brand owners, which can affect reimbursement and market entry speed.
- Post‑approval studies – if the FDA requires additional safety data, the generic may need to submit further reports before distribution.

How to stay informed
- FDA Drug Approval website – search for “formoterol” or “Respimat” to see current approvals.
- ClinicalTrials.gov – sometimes lists ongoing studies that could precede a generic launch.
- Pharma news outlets – sources such as FiercePharma or BioPharma Dive often report on upcoming generic launches and market strategy shifts.

Summary of the timeline
- Patent & exclusivity expiry – the starting point for generic filing.
- ANDA filing – followed by 12‑18 month FDA review.
- Approval – marks the legal permission to market.
- Market entry – depends on the sponsor’s launch readiness and market negotiations.

Until the FDA’s official approval is announced, the exact launch window for a Striverdi Respimat generic remains unknown.

Sources
[1] FDA. “Generic Drug Approvals.” https://www.fda.gov/drugs/drug-approvals-and-databases/generic-drug-approvals.